Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products
Biotechnology, Disease, Life Science News, NIH, Non-Profit Research, Pharmaceutical, Therapeutics, Vaccine
On Jul. 2, 2024, Emergent BioSolutions announced it had received more than $250 million
in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs).
These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.
Tags:
Source: Emergent BioSolutions
Credit: Photo: Microscopy of bacillus anthracis, courtesy Wikipedia.
